PTC Therapeutics Promotes Dr. Joseph McIntosh to SVP and Head of Clinical Development

7/24/17

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh, M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's portfolio.

"Dr. McIntosh's extensive experience and clinical management skills have been fundamental to PTC's development programs," said Marcio Souza, Chief Operating Officer, PTC Therapeutics, Inc. "Joe is a thoughtful leader committed to developing treatments for patients with rare diseases with significant unmet need. In this role, he will continue to help guide our programs as we approach critical clinical and regulatory milestones."

Dr. McIntosh joined PTC Therapeutics, Inc. in 2015 as Vice President, Clinical Development where he has been the lead clinician within the development group. Prior to joining PTC, Dr. McIntosh was Executive Director of Clinical Development of NPS Pharmaceuticals, responsible for managing and successfully coordinating cross functional program teams. Prior to NPS, he worked for Pfizer and Eisai where he assumed the role of clinical lead and program team lead for variety of development programs. Over the last several years, Joe has worked exclusively on rare diseases where he has led several development programs across hematology, hepatic and gastrointestinal therapeutic areas which include the successful initiation and completion of multiple phase 3 programs. Dr. McIntosh holds a medical degree from University of Witwatersrand, JHB, South Africa.

About PTC Therapeutics 

PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding nearly 20 years ago, PTC's mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and its corporate headquarters is located in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.